|Bid||5.20 x 2900|
|Ask||0.00 x 2900|
|Day's Range||5.63 - 5.85|
|52 Week Range||1.56 - 6.30|
|Beta (3Y Monthly)||2.87|
|PE Ratio (TTM)||5.87|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BOSTON, July 03, 2019 -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Drew Deniger, Ph.D., will join Ziopharm from the National Cancer.
Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP) today announced the initiation of a phase 2 clinical trial evaluating Controlled IL-12 (Ad-RTS-hIL-12 plus veledimex, Ad+V), in combination with PD-1 antibody Libtayo® (cemiplimab-rwlc) for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults. “We piloted the combination of interleukin-12 (IL-12) and a PD-1-specific antibody in a phase 1 trial which lays the foundation for recruitment to this phase 2 study for patients with rGBM. This trial seeks to further IL-12, which activates the patient’s own immune system to attack cancer, by coupling with the inhibition of PD-1 to enhance the effectiveness of the combination,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.
Investigators from this multi-center trial, conducted at Northwestern University in Chicago, Brigham and Women’s Hospital in Boston, and The University of Texas MD Anderson Cancer Center in Houston, have indicated interest in expanding the study and the Company now expects to enroll additional patients at the highest dosing level, subject to final agreement by the Data and Safety Monitoring Board. “We are pleased to complete enrollment of the dose escalation of Ad-RTS-hIL-12 + veledimex and nivolumab and explore the potential to expand this combination trial to further enrich our clinical experience,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.
Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced Heidi Hagen, an experienced and entrepreneurial biotechnology operations executive, has been appointed to the Company’s Board of Directors effective immediately.
Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP) announced that the investigational new drug (IND) application submitted by the National Cancer Institute (NCI) has received clearance from the U.S. Food and Drug Administration (FDA) for a clinical trial in solid tumors to evaluate T-cell receptor (TCR) T-cell therapy utilizing Ziopharm’s Sleeping Beauty platform. “This study is the result of extensive work by Dr. Steven Rosenberg and his team at the NCI, including Dr. Drew Deniger, to harness our Sleeping Beauty non-viral gene transfer technology to express neoantigen-specific T-cell receptors (TCRs),” said Dr. Laurence Cooper, Chief Executive Officer of Ziopharm.
BOSTON, June 02, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), a clinical stage immuno-oncology company developing next-generation cell and gene therapies, today announced the presentation of new interim analyses of clinical data from two ongoing substudies in its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults, at the American Society for Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31 to June 4, 2019. “Profiling an expanded number of patients with rGBM shows that Controlled IL-12 engages patients’ immune systems which we previously showed was an indicator of improved overall survival,” said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm.
– Scope of license includes library of T-cell receptors (TCRs) against neoantigens in hotspots including mutated KRAS, p53 and EGFR for use with Sleeping Beauty platform – –.
BOSTON, May 23, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that.
BOSTON, May 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced its financial results for the first quarter ended March 31, 2019, and provided an update on the Company’s recent activities. All three of our novel immuno-oncology programs are expected to be in the clinic this year,” said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm. “We are looking forward to treating patients with solid tumors mid-year with the first non-viral, neoantigen-specific TCR-T cell therapy at the National Cancer Institute (NCI).
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern ...
BOSTON, May 01, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Wednesday, May 8, at 4:30 p.m. ET to.
“Recurrent glioblastoma multiforme is an aggressive and life-threatening cancer of the central nervous system for which there are few treatment options and no cure,” said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm.
- Phase 1 Trial of Sleeping Beauty-TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 –- Third-generation Sleeping Beauty.
BOSTON, Feb. 25, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Tuesday, March 5,.
BOSTON, Feb. 21, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that Chief Executive Officer Laurence Cooper, M.D., Ph.D, is scheduled to present and participate.
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Ziopharm Oncology, Inc. (ZIOP) today announced that it rapidly completed enrollment and treated a total of 36 patients in less than six months in a substudy (Clinicaltrials.gov NCT03679754) to expand a Phase 1 trial evaluating its Controlled IL-12 platform as a monotherapy for the treatment of recurrent glioblastoma (rGBM). The trial was over enrolled with eleven more patients than the target goal of 25, which the Company attributes to enthusiasm stemming from the trial’s encouraging survival and tumor biopsy data. Ziopharm is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as a drug to control the production of interleukin 12 (IL-12).
The market for cell therapies of all kinds is exploding in size. Orgenesis Inc (ORGS) is making a name for itself as a top-notch provider of manufacturing to cell therapy drug developers. The company's revenue is growing consistently, and they recently achieved a key milestone under a 2018 investment agreement from a leading healthcare investment groups in the U.S., Great Point Partners.
HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold ...
The new license agreement helped pave the way for us to raise $50 million in a private placement from existing investors, secure a clinical collaboration with Regeneron Pharmaceuticals for Controlled IL-12 and announce a joint venture with committed funding of up to $35 million to bring our Sleeping Beauty platform for CD19-specific CAR-T to China. As we begin 2019, Ziopharm is already better.
Ziopharm Oncology, Inc. (ZIOP) today responded to the recent decline in the Company’s stock price, which accelerated greatly on December 26, 2018, the same day that the broader market and all indexes were up significantly. To the extent this price drop may have been attributable to any market confusion over exclusivity to its assets, the Company wishes to make clear the terms of its exclusivity to such assets. “Our stock price is significantly down of late, and we want to assure the market that our business fundamentals are unchanged and we are optimistic about Ziopharm’s future especially in light of the recent announcements we made with regards to our restructured relationship with Intrexon, the securing of a clean and longer-term balance sheet, and two partnerships with Regeneron and Eden BioCell.
CORAL GABLES, FL/ ACCESSWIRE / December 27,2018 / As the new year is rapidly approaching, companies in the healthcare sector are working tirelessly to create and implement nuanced methods for treating patients with a myriad of diseases and ailments. From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Allscripts Healthcare Solutions Inc (MDRX), ZIOPHARM Oncology Inc (ZIOP), and Sesen Bio Inc (SESN) are 4 healthcare stocks worth paying attention to before the end of the year. Premier Health Group (PHGRF) (PHGI), a company dominating the telehealth sector of the healthcare industry, has enjoyed a strong month of bullish trading, with Company shares soaring well above the 30% mark in a 30-day period.
BOSTON, Dec. 21, 2018 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 37th Annual J.P..
-- Joint venture to operate as Eden BioCell -- -- TriArm Therapeutics, a Panacea Venture Healthcare company, to fund Eden BioCell with up to $35M -- -- Ziopharm to license.
BOSTON, Dec. 13, 2018 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., has been promoted to President effective immediately. Dr. Mauney, who.